[1] Suryadevara CM, Verla T, Sanchez-Perez L, Reap EA, Choi BD, Fecci PE, Sampson JH. Immunotherapy for malignant glioma[J]. Surg Neurol Int, 2015, 6:68-77. [2] Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy[J]. Cancer Discov, 2018, 8:1069-1086. [3] Lu YC, Jia L, Zheng Z, Tran E, Robbins PF, Rosenberg SA. Single-cell transcriptome analysis reveals gene signatures associated with T-cell persistence following adoptive cell therapy[J]. Cancer Immunol Res, 2019, 7:1824-1836. [4] Gross G, Eshhar Z. Therapeutic potential of T cell chimeric antigen receptors (CARs) in cancer treatment:counteracting off-tumor toxicities for safe CAR T cell therapy[J]. Annu Rev Pharmacol Toxicol, 2016, 56:59-83. [5] Brown CE, Badie B, Barish ME, Weng L, Ostberg JR, Chang WC, Naranjo A, Starr R, Wagner J, Wright C, Zhai Y, Bading JR, Ressler JA, Portnow J, D'Apuzzo M, Forman SJ, Jensen MC. Bioactivity and safety of IL13R α 2-redirected chimeric antigen receptor CD8+T cells in patients with recurrent glioblastoma[J]. Clin Cancer Res, 2015, 21:4062-4072. [6] Filley AC, Henriquez M, Dey M. CART immunotherapy:development, success, and translation to malignant gliomas and other solid tumors[J]. Front Oncol, 2018, 8:453. [7] Srivastava S, Riddell SR. Engineering CAR-T cells:design concepts[J]. Trends Immunol, 2015, 36:494-502. [8] Eshhar Z, Waks T, Bendavid A, Schindler DG. Functional expression of chimeric receptor genes in human T cells[J]. J Immunol Methods, 2001, 248:67-76. [9] Adelain M, Brentjens R, Rivibre I. The promise and potential pitfalls of chimeric antigen receptors[J]. Curr Opin Immunol, 2009, 21:215-223. [10] Jensen MC, Riddell SR. Designing chimeric antigen receptors to effectively and safely target tumors[J]. Curr Opin Immunol, 2015, 33:9-15. [11] Chen D, Yang J. Development of novel antigen receptors for CAR T-cell therapy directed toward solid malignancies[J]. Transl Res, 2017, 187:11-21. [12] Jansen T, Tyler B, Mankowski JL, Recinos VR, Pradilla G, Legnani F, Laterra J, Olivi A. FasLgene knock-down therapy enhances the antiglioma immune response[J]. Neuro Oncol, 2010, 12:82-489. [13] ButteM J, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses[J]. Immunity, 2007, 27:111-122. [14] Loontz R. Breakthrough of the year 2013[J]. Science, 2013, 342:1442. [15] Ahmed N, Salsman VS, Kew Y, Shaffer D, Powell S, Zhang YJ, Grossman RG, Heslop HE, Gottschalk S. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors[J]. Clin Cancer Res, 2010, 16:474-485. [16] Sampson JH, Choi BD, Sanchez-Perez L, Suryadevara CM, Snyder DJ, Flores CT, Schmittling RJ, Nair SK, Reap EA, Norberg PK, Herndon JE 2nd, Kuan CT, Morgan RA, Rosenberg SA, Johnson LA. EGFRv Ⅲ mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss[J]. Clin Cancer Res, 2014, 20:972-984. [17] Tu M, Wange W, Cai L, Zhu P, Gao Z, Zheng W. IL-13 receptor α2 stimulates human glioma cell growth and metastasis through the Src/PI3K/Akt/mTOR signaling pathway[J]. Tumour Biol, 2016, 37:14701-14709. [18] Brown CE, Starr R, Aguilar B, Shami AF, Martinez C, D'Apuzzo M, Barish ME, Forman SJ, Jensen MC. Stem like tumor-initiating cells isolated from IL13Ralpha2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T cells[J]. Clin Cancer Res, 2012, 18:2099-2190. [19] Brown CE, Warden CD, Starr R, Deng X, Badie B, Yuan YC, Forman SJ, Barish ME. Glioma IL13R α 2 is associated with mesenchymal signature gene expression and poor patient prognosis[J]. PLoS One, 2013, 8:E77769. [20] Jarboe JS, Johnson KR, Choi Y, Lonser RR, Park JK. Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme:implications for targeted therapies[J]. Cancer Res, 2007, 67:7983-7986. [21] Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J, Kurien A, Priceman SJ, Wang X, Harshbarger TL, D'Apuzzo M, Ressler JA, Jensen MC, Barish ME, Chen M, Portnow J, Forman SJ, Badie B. Regression of glioblastoma after chimeric antigen receptor T-cell therapy[J]. N Engl J Med, 2016, 375:2561-2569. [22] Keu KV, Witney TH, Yaghoubi S, Rosenberg J, Kurien A, Magnusson R, Willisam J, Habte F, Wagner JR, Forman S, Brown C, Gambhir SS. Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma[J]. Sci Transl Med, 2017, 9:eaag2196. [23] Brown MP, Ebert LM, Gargett T. Clinical chimeric antigen receptor-T cell therapy:a new and promising treatment modality for glioblastoma[J]. Clin Transl Immunology, 2019, 8:E1050. [24] Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D, Robertson C, Gray TL, Diouf O, Wakefield A, Ghazi A, Gerken C, Yi Z, Ashoori A, Wu MF, Liu H, Rooney C, Dotti G, Gee A, Su J, Kew Y, Baskin D, Zhang YJ, New P, Grilley B, Stojakovic M, Hicks J, Powell SZ, Brenner MK, Heslop HE, Grossman R, Wels WS, Gottschalk S. HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma:a phase 1 dose-escalation trial[J]. JAMA Oncol, 2017, 3:1094-1101. [25] Bagley SJ, Desai AS, Linette GP, June CH, O'Rourke DM. CAR T-cell therapy for glioblastoma:recent clinical advances and future challenges[J]. Neuro Oncol, 2018, 20:1429-1438. [26] Li G, Wong AJ. EGF receptor variant Ⅲ as a target antigen for tumor immunotherapy[J]. Expert Rev Vaccines, 2008, 7:977-985. [27] Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, Reap EA, Feldman SA, Chinnasamy N, Kuan CT, Song H, Zhang W, Fine HA, Rosenberg SA. Recognition of glioma stem cells by genetically modified T cells targeting EGFRv Ⅲ and development of adoptive cell therapy for glioma[J]. Hum Gene Ther, 2012, 23:1043-1053. [28] Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH; ACT Ⅳ Trial Investigators. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRv Ⅲ-expressing glioblastoma (ACT Ⅳ):a randomised, double-blind, international phase 3 trial[J]. Lancet Oncol, 2017, 18:1373-1385. [29] O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJ, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV. A single dose of peripherally infused EGFRv Ⅲ-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma[J]. Sci Transl Med, 2017, 9:aaa0984. [30] Del Vecchio CA, Giacomini CP, Vogel H, Jensen KC, Florio T, Merio A, Pollack JR, Wong AJ. EGFRv Ⅲ gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms[J]. Oncogene, 2013, 32:2670-2681. [31] Felsberg J, Hentschel B, Kaulich K, Gramatzki D, Zacher A, Malzkorn B, Kamp M, Sabel M, Simon M, Westphal M, Schackert G, Tonn JC, Pietsch T, von Deimling A, Loeffler M, Reifenberger G, Weller M; German Glioma Network. Prognostic role of epidermal growth factor receptor variant Ⅲ(EGFRv Ⅲ) positivity in EGFR-amplified primary and recurrent glioblastomas[J]. Clin Cancer Res, 2017, 23:6846-6855. [32] Newick K, O'Brien S, Moon E, Albelda SM. CAR T cell therapy for solid tumors[J]. Annu Rev Med, 2017, 68:139-152. [33] Mirzaei R, Sarkar S, Yong VW. T cell exhaustion in glioblastoma:intricacies of immune checkpoints[J]. Trends Immunol, 2017, 38:104-115. [34] Hao C, Parney IF, Roa WH, Turner J, Petruk KC, Ramsay DA. Cytokine and cytokine receptor mRNA expression in human glioblastomas:evidence of Th1, Th2 and Th3 cytokine dysregulation[J]. Acta Neuropathol, 2002, 103:171-178. [35] Wei J, Wu A, Kong LY, Fuller G, Fokt I, Melillo G, Priebe W, Heimberger AB. Hypoxia potentiates glioma-mediated immunosuppression[J]. PLoS One, 2011, 6:E16195. [36] Qazi MA, Vora P, Venugopal C, Sidhu SS, Moffat J, Swanton C, Singh SK. Intratumoral heterogeneity:pathways to treatment resistance and relapse in human glioblastoma[J]. Ann Oncol, 2017, 28:1448-1456. [37] Aubry M, Tayrac MD, Etcheverry A, Clavreul A, Saikali S, Menei P, Mosser J. From the core to beyond the margin:a genomic picture of glioblastoma intratumor heterogeneity[J]. Oncotarget, 2015, 6:12094-12109. [38] Drent E, Groen RW, Noort WA, Themeli M, Lammerts van Bueren JJ, Parren PW, Kuball J, Sebestyen Z, Yuan H, de Bruijn J, van de Donk NW, Martens AC, Lokhorst HM, Mutis T. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma[J]. Haematologica, 2016, 101:616-625. |